Post-prophylaxis CMV in the letermovir era: Incidence, risk factors, and outcomes following HCT. (ASCO 2026) - Apr 21, 2026 - Abstract #6561; Pres time: Jun 1, 2026; 09:00 AM - 12:00 PM; Location: Hall A - Posters and Exhibits; Poster Bd #: 354; "HCT was most commonly for AML (48%), with matched unrelated donors (54%), peripheral blood graft (76%), myeloablative conditioning (45%), and GVHD ppx with post-transplant cyclophosphamide (PTCy) (63%)...Risk factors included older age (HR 1.04 per year, 95% CI=1.01-1.07, p=0.014), female sex (HR 3.3, 95% CI=1.5-7.1, p=0.003), chronic GVHD (HR 9.9, 95% CI=1.2-5.6, p=0.024), and GVHD treated with steroids (HR 9.86, 95% CI=1.4-71.5, p=0.024) or ruxolitinib (HR 2.8, 95% CI= 1.3-6.3, p=0.011)... Late csCMVi occurs in 12% of CMV+ HCT recipients after prophylaxis discontinuation and may confer additional mortality risk. These findings support risk-adapted surveillance and extended prophylaxis in high-risk groups, particularly recipients who are older, female, and have chronic GVHD requiring immunosuppression."
Clinical • Acute Graft versus Host Disease • Chronic Graft versus Host Disease • Cytomegalovirus Infection • Graft versus Host Disease • Immunology • Infectious Disease
|
|
Safah Khan; Elizabeth Darga; Kristina Nasr; Xuefei Jia; Andrew Trunk; Ronald Sobecks; Claudio Brunstein; Betty Hamilton; Zachary Yetmar
|